Any factor included as exclusion criteria in the participating centers treatment policy statement REGISTRATION EXCLUSION CRITERIA EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Patients receiving any other investigational agents EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Women who are pregnant or breastfeeding Olaparib\r\n* No additional exclusion criteria EXCLUSION CRITERIA FOR ENROLLMENT EXCLUSION CRITERIA FOR T CELL TREATMENT: PHASE I EXCLUSION CRITERIA Pregnancy or breastfeeding, or intending to become pregnant during the study Exclusion Criteria based on Organ Function or Medical History Cardiovascular Patients who meet the following cardiovascular exclusion criterion will be excluded from study entry: TREATMENT EXCLUSION CRITERIA EXCLUSION CRITERIA FOR REGISTRATION: Pregnant and/or breastfeeding EXCLUSION CRITERIA FOR REGISTRATION: Prior treatment with neratinib The following are considered criteria for exclusion from the exploratory genetic research: Medication-related exclusion criteria REGISTRATION/RANDOMIZATION EXCLUSION CRITERIA: Preoperative Exclusion Criteria Intraoperative Exclusion Criteria EXCLUSION CRITERIA FOR STRATA A, B, D AND E Subjects with CNS disease are eligible, with exceptions as noted in the exclusion criteria TREATMENT EXCLUSION CRITERIA TREATMENT EXCLUSION Cohort specific exclusion criteria (cohorts and groups without applicable specific exclusion criteria are not listed separately and should follow the general exclusion criteria) DONOR: The NMDP guidelines for exclusion criteria will be used. SCREENING PHASE EXCLUSION CRITERIA Ejection fraction < % will be an exclusion criteria for intensive chemotherapy; such patients may receive low intensity therapy SCREENING EXCLUSION CRITERIA Normal MRI exclusion criteria will apply; a standard MRI safety form will be used to identify potential conditions warranting exclusion MEDICATION-RELATED EXCLUSION CRITERIA ATEZOLIZUMAB-SPECIFIC EXCLUSION CRITERIA BEVACIZUMAB-SPECIFIC EXCLUSION CRITERIA RECIPIENT EXCLUSION CRITERIA IMMUNOTHERAPY-RELATED EXCLUSION CRITERIA MEDICATION-RELATED EXCLUSION CRITERIA: REGISTRATION- EXCLUSION ADDITION EXCLUSION CRITERIA FOR GROUP A (LOW TUMOR BURDEN) ONLY STEP SCREENING EXCLUSION CRITERIA COHORT EXCLUSION CRITERIA COHORT EXCLUSION CRITERIA REGISTRATION EXCLUSION CRITERIA EXCLUSION CRITERIA FOR ALL STUDY ARMS PART EXCLUSION CRITERIA: Subjects < . M^ DRUG-SPECIFIC EXCLUSION CRITERIA EXCLUSION CRITERIA (ENROLLMENT) EXCLUSION CRITERIA (TRANSPLANT) PANOBINOSTAT MAINTENANCE EXCLUSION EXCLUSION CRITERIA FOR SCREENING: EXCLUSION CRITERIA FOR LYMPHODEPLETION CHEMOTHERAPY, JCAR AND DURVALUMAB: EXCLUSION CRITERIA FOR PATIENTS WITH CLL, MCL, OR ALL (COHORT A) EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Platelet count < ,/mm^ EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Treatment with other investigational agent(s) within days of planned lymphodepletion EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Serum creatinine > . mg/dL EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): SGOT > x upper limit of normal EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Bilirubin > . mg/dL EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients who are HIV seropositive EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Women who are breastfeeding EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients who have contraindication to cyclophosphamide chemotherapy EXCLUSION CRITERIA FOR TNBC: ANC < /mm^ EXCLUSION CRITERIA FOR TNBC: Platelet count < ,/mm^ EXCLUSION CRITERIA FOR TNBC: Treatment with other investigational agent(s) within days of planned lymphodepletion EXCLUSION CRITERIA FOR TNBC: SGOT > x upper limit of normal EXCLUSION CRITERIA FOR TNBC: Bilirubin > . mg/dL EXCLUSION CRITERIA FOR TNBC: Patients who are HIV seropositive EXCLUSION CRITERIA FOR TNBC: Breast-feeding women EXCLUSION CRITERIA FOR TNBC: Patients who have contraindication to cyclophosphamide chemotherapy ENTRECTINIB EXCLUSION CRITERIA: Incomplete recovery from any surgery prior to treatment FIRST REGISTRATION-EXCLUSION: DONOR EXCLUSION CRITERIA: EXCLUSION CRITERIA - ARM A: EXCLUSION CRITERIA - ARM B: EXCLUSION CRITERIA FOR ENROLLMENT: The presence of active GVHD requiring treatment SCREENING EXCLUSION CRITERIA SCREENING EXCLUSION CRITERIA: INTRA-OPERATION EXCLUSION CRITERIA (RANDOMIZATION ARMS ONLY) Any patient ? and ? who presents for a colonoscopy and who does not have criteria for exclusion BEVACIZUMAB-SPECIFIC EXCLUSION CRITERIA: TREATMENT EXCLUSION CRITERIA: CHEMOTHERAPY/CELL INFUSION EXCLUSION CRITERIA: EXCLUSION CRITERIA FOR CONSENT B Other exclusion criteria: EXCLUSION CRITERIA AT TIME OF INFUSION: INTRAOPERATIVE EXCLUSION CRITERIA: Tumor type specific exclusion criteria EXCLUSION CRITERIA FOR REGISTRATION: mucinous adenocarcinoma, borderline tumors EXCLUSION CRITERIA FOR REGISTRATION: subjects who will undergo intraperitoneal chemotherapy TREATMENT EXCLUSION CRITERIA: EXCLUSION CRITERIA FOR CD+ TOPOFF WITHOUT CONDITIONING (COHORT ): Laboratory criteria for exclusion within days prior to randomization. Platelet count < x^ / L Exclusion criteria for Group Pregnant or lactation. Exclusion criteria for HSV-Tk infusion: PATIENT EXCLUSION CRITERIA: DONOR EXCLUSION CRITERIA: REGISTRATION EXCLUSION CRITERIA EXCLUSION CRITERIA FOR TREATMENT: Hct less than or equal to % EXCLUSION CRITERIA FOR TREATMENT: Hgb less than or equal to g/dL EXCLUSION CRITERIA FOR TREATMENT: ANC less than or equal to EXCLUSION CRITERIA FOR TREATMENT: Platelets less than or equal to , PHASE AND GENERAL EXCLUSION CRITERIA Patients should not enter the study if any of the following exclusion criteria are fulfilled ADDITIONAL EXCLUSION CRITERIA FOR PATIENTS IN COMBINATION FULVESTRANT/CABOZANTINIB COHORT SCREENING EXCLUSION CRITERIA: EXCLUSION CRITERIA FOR AUTOLOGOUS TRANSPLANT EXCLUSION CRITERIA FOR MAINTENANCE THERAPY Other Exclusion Criteria EXCLUSION CRITERIA: Must not meet any exclusion criteria defined in main study except for exclusion criteria \Subject must not have primary refractory disease\ which is related to prior carfilzomib EXCLUSION CRITERIA SEARCH PHASE Step I Exclusion Criteria: Step II Exclusion Criteria: TREATMENT EXCLUSION CRITERIA: MEDICATION-RELATED EXCLUSION CRITERIA METASTATIC SAFETY COHORT EXCLUSION CRITERIA NEOADJUVANT EXCLUSION CRITERIA EXCLUSION FOR ENROLLMENT/SCREENING (ARMS AND ) EXCLUSION FOR TREATMENT (ARMS AND ) Exclusion Criteria Arms B and C EXCLUSION CRITERIA PRIOR TO TRANSPLANT: STAGE I EXCLUSION CRITERIA: STAGE EXCLUSION CRITERIA: Exclusion of patients with creatinine > . Exclusion of patients with bilirubin > . There will be no exclusion criteria based on organ function There will be no exclusion criteria based on organ function. EXCLUSION CRITERIA - MAIN PROTOCOL EXCLUSION CRITERIA FOR CONTINUING THERAPY ON THE EXTENSION PHASE: Exclusion criteria will include all criteria listed for the main protocol EXCLUSION CRITERIA PRIOR TO CELL COLLECTIONS FOR DENDRITIC CELL GENERATION: EXCLUSION CRITERIA - RECIPIENT IBRUTINIB-SPECIFIC EXCLUSION CRITERIA IDELALISIB-SPECIFIC EXCLUSION CRITERIA CARDIAC EXCLUSION CRITERIA: There is no exclusion for the presence of cytopenias REGISTRATION # EXCLUSION CRITERIA Other Exclusion Criteria IMMUNOTHERAPY-RELATED EXCLUSION CRITERIA: RE-REGISTRATION EXCLUSION CRITERIA REGISTRATION EXCLUSION CRITERIA General Exclusion Criteria Prisoner -Impending Fracture-Specific Exclusion Criteria EXCLUSION CRITERIA FOR SCREENING: EXCLUSION CRITERIA FOR TREATMENT: EXCLUSION CRITERIA - INITIAL ENROLLMENT EXCLUSION CRITERIA FOR TRANSPLANT RECIPIENT EXCLUSION CRITERIA RELATED TO ZIV-AFLIBERCEPT No prior treatment with systemic chemotherapy (except as noted in exclusion criteria # ). Other Exclusion Criteria COHORT EXCLUSION CRITERIA FOR APHERESIS/TUMOR BIOPSY PORTION OF THE TRIAL (closed to enrollment as of //): COHORT EXCLUSION CRITERIA FOR IMMUNOTHERAPY PORTION OF THE TRIAL (closed to enrollment as of //): COHORT EXCLUSION CRITERIA: REGISTRATION EXCLUSION CRITERIA EXCLUSION CRITERIA FOR PATIENTS PATIENT EXCLUSION CRITERIA EXCLUSION CRITERIA-PATIENTS EXCLUSION CRITERIA-FCGs EXCLUSION CRITERIA FOR PARENTS: Patient declines assent/consent (if >= years) EXCLUSION CRITERIA FOR PARENTS: Parent or child participated on prior PRISM intervention study EXCLUSION CRITERIA FOR PATIENTS: Patient declines assent/consent (if >= years) EXCLUSION CRITERIA FOR PATIENTS: Patient participated on a prior PRISM intervention study EXCLUSION - STUDY : Parkinson's disease EXCLUSION - STUDY : The inclusion/exclusion criteria follows similar criteria for study # except only patients with confirmed peripheral neuropathy (VPT big toe greater than volt) will be included; patients who have completed clinical study would be eligible for study if they develop CIPN as defined by VPT assessment EXCLUSION CRITERIA FOR PATIENT PARTICIPANTS PHASE : No provider exclusion criteria PHASE A/B: PATIENT EXCLUSION CRITERIA: Non-English speaker EXCLUSION CRITERIA SPECIFIC TO SURVIVORS: EXCLUSION CRITERIA FOR BOTH SURVIVORS AND CO-SURVIVORS: EXERCISE EXCLUSION CRITERIA: There are no other agent-specific exclusion criteria EXCLUSION CRITERIA FOR FOCUS GROUPS (PHASE I) PATIENT EXCLUSION CRITERIA: PREPROCEDURAL EXCLUSION CRITERIA: PATIENTS EXCLUSION CRITERIA: Hepatic encephalopathy Exclusion Criteria Specific to Arm B (Gastric Cancer) (Patients who meet any of the following specific exclusion criteria will be excluded from enrollment in Arm B:) Ongoing treatment for epilepsy Exclusion Criteria Specific to Arm C (Metastatic Pancreatic Cancer) (Patients who meet any of the following specific exclusion criteria will be excluded from enrollment in Arm C:) PATIENT PARTICIPANT EXCLUSION CRITERIA (PHASE & ) EXCLUSION CRITERIA FOR GROUP A AND B EXCLUSION CRITERIA-PATIENTS Pre-procedure Exclusion Criteria GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Patients who have an uncontrolled infection are not eligible READER STUDY EXCLUSION REGISTRATION EXCLUSION REGISTRATION EXCLUSION: REGISTRATION EXCLUSION CRITERIA REGISTRATION EXCLUSION CRITERIA EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Pregnant or breastfeeding EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Karnofsky performance status < % EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Karnofsky performance status < % EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Any uncontrolled active systemic infection EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Lactating or pregnant EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Uncontrolled cardiac arrhythmias REGISTRATION/RANDOMIZATION EXCLUSION CRITERIA Exclusion criteria for RPFNA Exclusion criteria for study intervention DRIVERS EXCLUSION CRITERIA Exclusion Criteria for C-MBT studies: Exclusion Criteria for P-MRS studies Eligible for donation according to the transplantation center Exclusion Criteria Donor: A history of miscarriage in the last months, in and of itself, will not be considered an exclusion Good performance status (as defined in Exclusion Criteria) REGISTRATION EXCLUSION CRITERIA EXCLUSION CRITERIA FOR CALYPSO TRANSPONDERS: EXCLUSION CRITERIA (ALL PATIENTS) Evidence of metastases (pelvic lymph node involvement is not an exclusion criteria); for patients with recurrent prostate cancer, oligometastatic disease ( or fewer visible metastases) is not an exclusion criterion EXCLUSION CRITERIA FOR ORAL LESION AND NORMAL TISSUE EXCLUSION CRITERIA FOR DRY MOUTH STUDY EXCLUSION CRITERIA FOR GUM STUDY No other appropriate agent-specific exclusion criteria CANCER-SPECIFIC EXCLUSION CRITERIA GENERAL MEDICAL EXCLUSION CRITERIA STEP : EXCLUSION CRITERIA FOR TUMOR COLLECTION Subject Exclusion Criteria for Optional Contrast MRIs Cohort Only: Common exclusion criterion EXCLUSION CRITERIA - FOR MALE COHORT SITE EXCLUSION CRITERIA: PATIENT EXCLUSION CRITERIA: PATIENT PARTICIPANTS EXCLUSION CRITERIA: DRIVER EXCLUSION: TRIAL EXCLUSION: PATIENT EXCLUSION: PROSPECTIVE STUDY POPULATION EXCLUSION CHART AUDIT EXCLUSION CRITERIA: There are no specific exclusion criteria for this study. No exclusion criteria for this study Other Exclusion Criteria